相关实验视频

Updated: Jun 29, 2025

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

伊科萨乙烯调节循环血管再生细胞的含量:IPE-PREVENTION CardioLink-14试验

Ehab Bakbak¹, Aishwarya Krishnaraj², Deepak L Bhatt³

¹Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, ON, Canada; Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.

Med (New York, N.Y.)

|March 29, 2024

概括

伊可萨乙烯 (IPE) 治疗增加了有益的血管再生细胞,并减少了患有高甘油三血症的患者的氧化应激. 这表明了IPE的新机制.

科学领域:

心血管医学心血管医学
翻译科学翻译科学
再生医学是一种再生医学.

背景情况:

REDUCE-IT试验表明,icosapent乙烯 (IPE) 降低了心血管事件的25%.
基础上IPE的心脏保护作用的机制仍然不完全理解.
在IPE-PREVENTION CardioLink-14试验中,研究了IPE对血管再生细胞的影响.

研究的目的:

为了确定IPE是否调节轻度至中度高甘油三血症患者的血管再生 (VR) 细胞含量.
探索IPE心脏保护作用的潜在新机制.

主要方法:

七十名接受他类药物治疗的患有高甘油三血症的患者随机分配到IPE或常规护理.
分离和鉴定了具有高阿尔代脱酶活性 (ALDH) 的血管再生细胞.
主要终点:亲血管ALDH^hiCD133⁺祖先细胞的频率的变化.

主要成果:

与通常的护理相比,IPE显著增加了ALDH^hiCD133⁺原始细胞的频率.
在ALDH^hiSSC^low祖先中,IPE降低了氧化应激.
IPE还增加了ALDH^hiSSC^hi粒细胞前体细胞含量.

结论:

预防IPE CardioLink-14提供了IPE调节VR细胞内容的第一个翻译证据.
这种VR细胞的调制表明了IPE心脏保护作用的新机制.
这些发现支持进一步调查IPE在血管再生和心血管事件减少中的作用.

关键词:

翻译给患者使用.化物化物化物心血管疾病心血管疾病颗粒细胞是颗粒细胞.艾科萨乙烯 (icosapent ethyl) 的使用情况欧米茄-3 脂肪酸-3 脂肪酸原始细胞是原始细胞.船舶维修船舶维修公司

更多相关视频

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Clinical Applications of Epidermal Stem Cells

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...